Table 1

Comparison of the clinical characteristics of the infants receiving oral erythromycin and those receiving placebo

Clinical features Oral erythromycin group
(n=27)
Placebo group
(n=29)
Gestational age (weeks)29.6 (28.6–30.7)29.3 (27.5–31.0)
Birth weight (g)1180 (985–1395)1160 (1004–1389)
Sex (female : male)12 (44%) : 15 (56%)15 (52%) : 14 (48%)
Inborn : Outborn26 (96%) : 1 (4%)28 (97%) : 1 (3%)
Mode of delivery1-150
 Vaginal6 (22%)15 (52%)
 Caesarean section20 (74%)14 (48%)
 Forceps1 (4%)0 (0%)
Apgar scores
 1 min7 (5–8)6 (5–7)
 5 min9 (8–9)9 (8–9)
Umbilical arterial blood gas variables
 pH7.29 (7.23–7.32)7.29 (7.19–7.32)
 Base excess−4.1 (−5.6–−2.3)−6.1 (−9.0–−0.8)
First venous haematocrit after delivery0.52 (0.44–0.54)0.50 (0.42–0.54)
Temperature on admission (°C)36.2 (36.0–36.6)36.3 (36.0–36.8)
Umbilical arterial catheter:
 Infants with UAC (n)14 (52%)18 (62%)
 Duration (days)8 (7–14)6.5 (5–13)
Umbilical venous catheter:
 Infants with UVC (n)20 (74%)23 (79%)
 Duration (days)14 (8–17)13.5 (6–17)
Respiratory distress syndrome
 Grade 0–214 (52%)14 (48%)
 Grade 3–413 (48%)15 (52%)
Drugs
 Antenatal dexamethasone
  Number of mothers24 (89%)25 (86%)
  Doses (n)2 (1–4)2 (1–4)
  Indomethacin
  Number of infants10 (37%)12 (41%)
 Fentanyl
  Number of infants22 (82%)25 (86%)
  Duration (days)5 (1–7)3 (1–11)
 Vecuronium
  Number of infants8 (30%)12 (41%)
  Duration (days)0 (0–2)0 (0–2)
  • Continuous variables are expressed in median (interquartile ranges) and proportions in number of patients (%);

  • 1-150 p<0.05.

  • UAC, Umblical arterial catheter; UVC, umbilical venous catheter.